The Increasing Use of Personalized Medicine And Advancements In Treatment Options Have Propelled The Growth Of The Intratumoral Cancer Therapies Market In The North America Region!
- Himanshu Patni
- November 17, 2023
- HEALTHCARE, NEWS
- Intratumoral Cancer Therapies Market, Intratumoral Cancer Therapies Market Share, Intratumoral Cancer Therapies Market Size, Intratumoral Cancer Therapies Market Trends
- 0 Comments
Intratumoral cancer therapies are a type of cancer treatment that involves delivering therapeutic agents directly into the tumour site. Unlike systemic treatments, which circulate throughout the entire body, intratumoral therapies target cancer cells within the tumour while minimizing exposure to healthy tissues. Growing advancements in immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapies, and oncolytic viruses, are driving interest in intratumoral applications. These therapies stimulate the body’s immune response to target and destroy cancer cells directly within the tumour site. For instance, in February 2021, the FDA approved Merck’s Keytruda (pembrolizumab) for the treatment of high-risk, non-muscle invasive bladder cancer unresponsive to BCG therapy.
Access sample report (including graphs, charts, and figures) – https://univdatos.com/get-a-free-sample-form-php/?product_id=46877
This approval highlights the potential of immunotherapies in intratumoral applications. Furthermore, the trend toward personalized medicine is driving the development of intratumoral therapies tailored to individual patients’ genetic profiles and tumour characteristics. This approach improves treatment effectiveness and reduces side effects. The increasing use of personalized medicine and advancements in treatment options are playing a significant role in boosting the intratumoral cancer therapies market in the United States. Intratumoral cancer therapies are a promising approach to cancer treatment. These therapies involve administering therapeutic agents directly into the tumor site, which helps to limit exposure to healthy tissues. Unlike systemic treatments that circulate throughout the entire body, intratumoral therapies target cancer cells within the tumor. This targeted approach can help to increase the effectiveness of the treatment while minimizing side effects. The rising prevalence of cancer is the main factor in boosting the intratumoral cancer therapies market in this region. For instance, according to the American Cancer Society, in the United States, In 2022, over 1.9 million new cancer cases are expected to be identified in the US in 2022. In addition, advancements in immunotherapy lead to improved outcomes for patients and are likely to boost the growth of the intratumoral cancer therapies market. Furthermore, Canada has a strong and growing healthcare industry, with a focus on developing cutting-edge therapies and technologies for cancer patients. This has led to significant investments in the research and development of novel therapies and targeted therapies for cancer, which in turn has accelerated the adoption of the intratumoral cancer therapies market. additionally, the increasing prevalence of cancer and technological innovations in therapies have synergistically contributed to the growth of the intratumoral cancer therapies market. Also, Companies like AbbVie Inc, AstraZeneca, and Eli Lily have been at the forefront of introducing novel technologies and advanced imaging to enhance the quality of visualization and staging of cancer tumours. These advancements not only improve treatment outcomes but also empower patients to actively participate in diagnosis campaigns, leading to better disease control.
Further, the North America Intratumoral cancer therapies Market is expected to grow at a strong CAGR of 9.9% during the forecast period (2023-2030). In conclusion, the growth of the intratumoral cancer therapies market in North America is a result of a combination of factors, including the increasing use of personalized medicine and advancements in treatment options, increasing healthcare expenditure, and increasing prevalence of cancer.
North America Intratumoral cancer therapies Market Revenue (2020-2030)- USD bn
For a detailed analysis of the Global Intratumoral Cancer Therapies Market browse through – https://univdatos.com/report/intratumoral-cancer-therapies-market/
Based on the technology, the market has been categorized into monoclonal antibodies, cell and gene therapies, cytokines, and others. Among them, the monoclonal antibodies segment is expected to grow at a higher CAGR in the market due to their potential to target specific cancer cells, trigger immune responses, and minimize off-target effects. Monoclonal antibodies have been widely used in systemic cancer treatments, and their application in intratumoral therapies is gaining traction due to their precision and effectiveness.
Based on the application, the market has been categorized into lung cancer, breast, melanoma, prostate cancer, and others. Among them, the lung cancer segment is expected to grow at a higher CAGR in the market due to the high incidence of lung cancer and the increasing adoption of innovative therapies to address this challenging disease. Moreover, standard treatments for lung cancer, such as surgery, chemotherapy, and radiation, can have limitations and significant side effects. Intratumoral therapies aim to address these challenges by targeting the tumor cells while minimizing damage to healthy tissues.
Global Intratumoral Cancer Therapies Market Segmentation
Market Insight, by Technology
· Monoclonal Antibodies
· Cell And Gene Therapies
· Cytokines
· Others
Market Insight, by Application
· Lung Cancer
· Breast
· Melanoma
· Prostate Cancer
· Others
Market Insights, by End-Users
· Hospitals
· Radiation Therapy Center
· Cancer Research Institutes
Market Insight, by Region
· North America Intratumoral cancer therapies Market
o U.S.
o Canada
o Rest of North America
· Europe Intratumoral cancer therapies Market
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
· Asia-Pacific Intratumoral cancer therapies Market
o China
o India
o Japan
o Rest of Asia-Pacific
· Rest of the World Intratumoral cancer therapies Market
Top Company Profiles
· AstraZeneca
· Amgen Inc.
· Eli Lilly and Company
· AbbVie Inc.
· F. Hoffmann-La Roche Ltd
· Novartis AG
· Merck & Co., Inc
· Bayer AG
· Pfizer Inc.
· Bristol-Myers Squibb Co.